Nautilus Biotechnology reports a Q2 GAAP EPS of -$0.11, beating estimates, as revenue climbs to $0.19M on grant and service sales.
Nautilus Biotechnology reported a Q2 GAAP loss per share of $0.11, narrower than the expected loss by $0.03. Revenue reached $0.19 million, up from negligible levels in prior periods.
The company attributed the revenue increase to grant funding from The Michael J. Fox Foundation and initial sales under its Iterative Mapping Early Access Program. Revenue for the same period in 2026 was $0.2 million, driven by similar activities.
Shares rose 3% in premarket trading following the announcement.